We advised Oruka on the offering

Davis Polk advised Oruka Therapeutics, Inc. on its $700 million follow-on offering of 9,660,000 shares of common stock. The shares of common stock are listed on the Nasdaq Global Market under the symbol “ORKA.”

Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Paula Gergen and Matthew Kenney. The tax team included partner William A. Curran, counsel Yixuan Long and associate Hunter P. Shaw. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post